This report was first published by Endpoints News. To see the original version, click here
The leader of the FDA’s drug division, Tracy Beth Høeg, is expected to depart the agency, as part of a broad shakeup at the top of the agency after the exit of now-former commissioner Marty Makary, according to an internal message reviewed by Endpoints News.
Høeg will be replaced as acting director by Michael Davis, a longtime FDA executive, according to an internal message from Acting Commissioner Kyle Diamantas. CBER Acting Director Katherine Szarama will also be replaced by Karim Mikhael, a former biopharma executive who joined the agency last year.
您已阅读23%（647字），剩余77%（2208字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。